Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
22 pending office actions • 14 art units • 21 examiners • 0 of 22 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Laboratory Corporation of America Holdings has 22 pending office actions in Biotechnology & Pharmaceuticals. The matters span 21 distinct examiners and 14 distinct art units, reflecting broad distribution across both examiner assignments and technical groups.
ZOU, NIANXIANG is the busiest examiner, with 2 pending matters. The limited concentration under that examiner means the principal management challenge is coordination across many separate prosecution tracks rather than reliance on one examiner relationship. Counsel should use centralized claim and disclosure controls, while tailoring prior-art analysis, amendments, and interview strategy to each art unit.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §101 + other | 9 (41%) |
| §103 only | 3 (14%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 2 (9%) |
| Multi-statute (no §101) | 6 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 2 | 64.0% | +25.0% |
| KANAAN, MAROUN P | 1 | 62.7% | +31.7% |
| DOUGHERTY, SEAN PATRICK | 1 | 74.5% | +16.1% |
| BELYAVSKYI, MICHAIL A | 1 | 63.9% | +28.0% |
| NGUYEN, TRAN N | 1 | 61.8% | +16.9% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| PARK, HYUN D | 1 | 41.8% | +22.5% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| CHOI, DAVID | 1 | 20.0% | +29.8% |
| ALABI, OYELEYE A | 1 | 83.9% | +23.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18451730 | PREDICTING AN ANIMAL HEALTH RESULT FROM LABORATORY TEST MONITORING | CHOI, DAVID | 35d overdue |
| 18107877 | Methods and Systems for Detecting Methylation of Fragile X | SCHLOOP, ALLISON ELIZABETH | 4d overdue |
| 17845629 | Methods and Systems for Detection of Covid Variants | ZOU, NIANXIANG | 20d |
| 19027178 | CLINICAL LABORATORY-BASED DISEASED MANAGEMENT PROGRAM, WITH AUTOMATED PATIENT-SPECIFIC TREATMENT ADVICE | KANAAN, MAROUN P | — |
| 18968942 | METHODS AND SYSTEMS FOR IMPROVING CAPILLARY BLOOD DRAW AND COLLECTION | DOUGHERTY, SEAN PATRICK | — |
| 18424298 | BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY | BELYAVSKYI, MICHAIL A | — |
| 18411772 | METHODS AND SYSTEMS FOR THE RAPID DETECTION OF SALMONELLA USING INFECTIOUS AGENTS | ZOU, NIANXIANG | — |
| 18542284 | VISUALIZATION OF AND INTERACTION WITH CLINICAL DATA | NGUYEN, TRAN N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18451730 | PREDICTING AN ANIMAL HEALTH RESULT FROM LABORATORY TEST MONITORING | CHOI, DAVID | 35d overdue |
| 17845629 | Methods and Systems for Detection of Covid Variants | ZOU, NIANXIANG | 20d |
| 19027178 | CLINICAL LABORATORY-BASED DISEASED MANAGEMENT PROGRAM, WITH AUTOMATED PATIENT-SPECIFIC TREATMENT ADVICE | KANAAN, MAROUN P | — |
| 18968942 | METHODS AND SYSTEMS FOR IMPROVING CAPILLARY BLOOD DRAW AND COLLECTION | DOUGHERTY, SEAN PATRICK | — |
| 18424298 | BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY | BELYAVSKYI, MICHAIL A | — |
| 18411772 | METHODS AND SYSTEMS FOR THE RAPID DETECTION OF SALMONELLA USING INFECTIOUS AGENTS | ZOU, NIANXIANG | — |
| 18542284 | VISUALIZATION OF AND INTERACTION WITH CLINICAL DATA | NGUYEN, TRAN N | — |
| 18559553 | TECHNIQUES FOR DIAGNOSING SOURCES OF ERROR IN A SAMPLE PROCESSING WORKFLOW | PARK, HYUN D | — |
| Art Unit | Apps |
|---|---|
| 1671 | 4 |
| 1672 | 3 |
| 1686 | 2 |
| 1687 | 2 |
| 3687 | 1 |
| 1644 | 1 |
| 3685 | 1 |
| 2857 | 1 |
| 3684 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19027178 | CLINICAL LABORATORY-BASED DISEASED MANAGEMENT PROGRAM, WITH AUTOMATED PATIENT-SPECIFIC TREATMENT ADVICE | KANAAN, MAROUN P | 3687 | §101§103Other | Non-Final OA | — | Pending | Jan 17, 2025 |
| 18968942 | METHODS AND SYSTEMS FOR IMPROVING CAPILLARY BLOOD DRAW AND COLLECTION | DOUGHERTY, SEAN PATRICK | — | §102§112 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18424298 | BIOMARKERS AND METHODS FOR MEASURING AND MONITORING JUVENILE IDIOPATHIC ARTHRITIS ACTIVITY | BELYAVSKYI, MICHAIL A | 1644 | §101DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18411772 | METHODS AND SYSTEMS FOR THE RAPID DETECTION OF SALMONELLA USING INFECTIOUS AGENTS | ZOU, NIANXIANG | 1671 | §102§103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18542284 | VISUALIZATION OF AND INTERACTION WITH CLINICAL DATA | NGUYEN, TRAN N | 3685 | §101 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18506364 | SYNTHETIC PHAGE WITH RECOMBINANT TAIL-SPIKE PROTEINS AND RELATED METHODS | ALAM, DANYAL HASSAN | 1672 | §102§103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18559553 | TECHNIQUES FOR DIAGNOSING SOURCES OF ERROR IN A SAMPLE PROCESSING WORKFLOW | PARK, HYUN D | 2857 | §101§102§103 | Final Rejection | — | Pending | Nov 07, 2023 |
| 18500048 | METHODS AND SYSTEMS FOR DETECTION OF MONKEYPOX VIRUS | GILL, RACHEL B | 1671 | §103§112 | Final Rejection | — | Pending | Nov 01, 2023 |
| 18451730 | PREDICTING AN ANIMAL HEALTH RESULT FROM LABORATORY TEST MONITORING | CHOI, DAVID | 3684 | §101§103§112 | Non-Final OA | 35d overdue | Pending | Aug 17, 2023 |
| 18366599 | METABOLIC VULNERABILITY ANALYZED BY NMR | ALABI, OYELEYE A | 1678 | §101§103§112 | Final Rejection | — | Pending | Aug 07, 2023 |
| 18210959 | Multi-Parameter Diabetes Risk Evaluations | NEGIN, RUSSELL SCOTT | 1686 | §101DP | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18131262 | Methods, Compositions and Systems for Respiratory Virus Detection | ALLEN, MICHAEL D | 1671 | §103 | Final Rejection | 28d overdue | Pending | Apr 05, 2023 |
| 18188943 | Metabolic Markers of Attention Deficit Hyperactivity Disorder | SCHMITT, MICHAEL J | 1629 | §112Other | Final Rejection | — | Pending | Mar 23, 2023 |
| 18107877 | Methods and Systems for Detecting Methylation of Fragile X | SCHLOOP, ALLISON ELIZABETH | 1683 | §103§112 | Final Rejection | 4d overdue | Pending | Feb 09, 2023 |
| 18081459 | SYSTEMS AND METHODS FOR THE INTERPRETATION OF GENETIC AND GENOMIC VARIANTS VIA AN INTEGRATED COMPUTATIONAL AND EXPERIMENTAL DEEP MUTATIONAL LEARNING FRAMEWORK | LEVERETT, MARY CHANG | 1672 | §101§103§112 | Non-Final OA | — | Pending | Dec 14, 2022 |
| 17802913 | Methods and Systems to Determine HLA-DPB1 Expression | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§103§112 | Non-Final OA | — | Pending | Aug 26, 2022 |
| 17845629 | Methods and Systems for Detection of Covid Variants | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | 20d | Pending | Jun 21, 2022 |
| 17739978 | ASSAYS FOR SINGLE MOLECULE DETECTION AND USE THEREOF | DAUNER, JOSEPH G | 1682 | §103 | Non-Final OA | — | Pending | May 09, 2022 |
| 17534043 | Methods and Systems for the Detection of Microorganisms Using Infectious Agents | WANG, RUIXUE | 1672 | §103 | Final Rejection | 5d overdue | Pending | Nov 23, 2021 |
| 17464061 | BIOMARKERS AND METHODS FOR MEASURING AND MONITORING AXIAL SPONDYLOARTHRITIS ACTIVITY | ANDERSON-FEARS, KEENAN NEIL | 1687 | §103§112DP | Final Rejection | 8d overdue | Pending | Sep 01, 2021 |
| 17443124 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT PATHOGEN TESTING | LIU, GUOZHEN | 1686 | §101§112Other | Non-Final OA | — | Pending | Jul 21, 2021 |
| 17348706 | Methods for the Diagnosis and Treatment of Biofilm-Related Infections | BUTTICE, AUDREY L | 1647 | §103§112DP | Non-Final OA | 97d overdue | Pending | Jun 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLaboratory Corporation of America Holdings has 22 pending office actions as of October 2026, spread across 14 art units and 21 examiners.
Nianxiang Zou has the most, with 2 of Laboratory Corporation of America Holdings's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.